医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Quintiles’ Anand Tharmaratnam Honored as ‘Asian Male Executive of the Year’ in BioPharma Asia Industry Awards 2015

2015年03月25日 AM09:30
このエントリーをはてなブックマークに追加


 

SINGAPORE

Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., last night was honored as “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards. Dr. Tharmaratnam was selected in a vote of biopharmaceutical industry professionals from five distinguished executives shortlisted for the award.

Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., accepts 'Asian Male Executive of the Year'  ...

Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., accepts ‘Asian Male Executive of the Year’ honors at the BioPharma Asia Industry Awards dinner Tuesday night (24 March) in Singapore. (Photo: Business Wire)

“On behalf of the hundreds of voters who made their voices heard in the competition, we are pleased to present this award to Dr. Tharmaratnam,” said Sharon Roessen, Managing Director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2015. “His visionary leadership and Quintiles’ stellar work were frequent themes in voter comments. We would like to thank Anand for his contributions to advancing Asia’s biopharma industry.”

Over the past 11 years, Dr. Tharmaratnam has led Quintiles’ expansion in size and service offerings across the region. Quintiles now has more than 10,000 employees in 13 Asia-Pacific countries with half the world’s population – including China and Japan, respectively the world’s second- and third-largest biopharma markets. In 2014, Quintiles Asia-Pacific’s service revenues were $858 million USD.

“I am honored and humbled to have won this award,” Dr. Tharmaratnam said at last night’s awards dinner in Singapore. “I’d like to dedicate this award to my fellow Quintiles colleagues and to our customers who entrust us with advancing their investigational therapies to save lives and relieve suffering. Together we are creating a healthier world.”

Quintiles has won BioPharma Asia’s “Best CRO in Asia” award three times in the event’s five-year history, and last year – for the sixth time in eight years – was named Asia-Pacific CRO of the Year by Frost & Sullivan, a leading business research and consulting firm.

At this week’s BioPharma Asia Convention, Quintiles’ experts Dr. Karen Wai and Edwin Sia led roundtables on “Pan-Asian clinical trials coordination” and “Improving clinical supply importation and exportation,” respectively, and Wendy Bilham, Quintiles’ Head of Therapeutic Science and Strategy, Asia-Pacific, presented a case study on “Improving your probability of success in clinical trials in Asia.”

About Quintiles

Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150324006239/en/

CONTACT

Quintiles
Jay Johnson, Media Relations, +65-6602-1297
Mobile:
+65-9655-6635
jay.johnson@quintiles.com
or
Karl
Deonanan, Investor Relations, +1-919-998-2789
InvestorRelations@quintiles.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表